Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacokinetics of pantoprazole in man.
Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K. Huber R, et al. Int J Clin Pharmacol Ther. 1996 May;34(5):185-94. Int J Clin Pharmacol Ther. 1996. PMID: 8738854 Clinical Trial.
Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins. ...In patients with sev …
Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of abou …
Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Ullmann U, Lehnfeld R, Bliesath H, Birkel M, Gebbing H, Gräve M, Wolf H. Ullmann U, et al. Among authors: bliesath h. Int J Clin Pharmacol Ther. 2001 Jun;39(6):271-6. Int J Clin Pharmacol Ther. 2001. PMID: 11430636 Clinical Trial.
Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers.
Bauer M, Bliesath H, Leuratti C, Lackner E, Dieterle W, Müller M, Brunner M. Bauer M, et al. Among authors: bliesath h. Pharmacology. 2010;86(5-6):297-305. doi: 10.1159/000321322. Epub 2010 Nov 11. Pharmacology. 2010. PMID: 21071997 Clinical Trial.
Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.
Schulz HU, Hartmann M, Steinijans VW, Huber R, Lührmann B, Bliesath H, Wurst W. Schulz HU, et al. Int J Clin Pharmacol Ther. 1996 May;34(1 Suppl):S51-7. Int J Clin Pharmacol Ther. 1996. PMID: 8793603 Clinical Trial.
Steady-state serum theophylline concentrations were obtained by a two-step intravenous infusion scheme of approximately 350 mg theophylline each over 0.5 h and subsequently over approximately 10 h, respectively. ...Serum pantoprazole concentrations were measured up …
Steady-state serum theophylline concentrations were obtained by a two-step intravenous infusion scheme of approximately 350 mg theophylline …
Pantoprazole and 24-hour intragastric acidity.
Hartmann M, Bliesath H, Lühmann R, Wurst W. Hartmann M, et al. Aliment Pharmacol Ther. 1993 Feb;7(1):115-6. doi: 10.1111/j.1365-2036.1993.tb00077.x. Aliment Pharmacol Ther. 1993. PMID: 8439633 Clinical Trial. No abstract available.
Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B, Müller P, Hartmann M, Bliesath H, Lühmann R, Huber R, Bohnenkamp W, Wurst W. Simon B, et al. Z Gastroenterol. 1990 Sep;28(9):443-7. Z Gastroenterol. 1990. PMID: 2177296
The objective of the study was to investigate the pharmacodynamics and pharmacokinetics of the gastric H+, K(+)-ATPase inhibitor pantoprazole in man following repeated i.v. dosing. 8 healthy male volunteers aged from 25 to 31 years (median: 29 years), body weight between 7 …
The objective of the study was to investigate the pharmacodynamics and pharmacokinetics of the gastric H+, K(+)-ATPase inhibitor pant …
Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.
Duursema L, Müller FO, Schall R, Middle MV, Hundt HK, Groenewoud G, Steinijans VW, Bliesath H. Duursema L, et al. Br J Clin Pharmacol. 1995 Jun;39(6):700-3. doi: 10.1111/j.1365-2125.1995.tb05732.x. Br J Clin Pharmacol. 1995. PMID: 7654493 Free PMC article. Clinical Trial.
The 90% confidence intervals for the 'test/reference' mean ratios of the excess AUC(0.168 h) of prothrombin time and AUC(0.168 h) of factor VII, and of Cmax, AUC and t1/2 of both R- and S-warfarin fell within the equivalence range of 80% to 125%. ...
The 90% confidence intervals for the 'test/reference' mean ratios of the excess AUC(0.168 h) of prothrombin time and AUC(0.168 h
Pantoprazole lacks induction of CYP1A2 activity in man.
Hartmann M, Zech K, Bliesath H, Steinijans VW, Koch H, Wurst W, Mascher H. Hartmann M, et al. Among authors: bliesath h. Int J Clin Pharmacol Ther. 1999 Apr;37(4):159-64. Int J Clin Pharmacol Ther. 1999. PMID: 10235417 Clinical Trial.
Pantoprazole does not interact with the pharmacokinetics of carbamazepine.
Huber R, Bliesath H, Hartmann M, Steinijans VW, Koch H, Mascher H, Wurst W. Huber R, et al. Among authors: bliesath h. Int J Clin Pharmacol Ther. 1998 Oct;36(10):521-4. Int J Clin Pharmacol Ther. 1998. PMID: 9799054 Clinical Trial.
Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man.
Ehrlich A, Fuder H, Hartmann M, Wieckhorst G, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Ehrlich A, et al. Eur J Clin Pharmacol. 1996;51(3-4):277-81. doi: 10.1007/s002280050198. Eur J Clin Pharmacol. 1996. PMID: 9010699
40 results
Jump to page
Feedback